PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.88 +5.29%

+$0.09 today

Market cap
$268.73M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 5.61M

Average 1.37M

PEPG EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

PepGen Inc.NASDAQ: PEPG

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$17.43M, compared with -$28.88M a year earlier. Trailing-twelve-month EBITDA was -$75.99M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +1.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.43M+8.6% QoQ
Last fiscal yearDec 2025
-$88.21M+1.0% YoY
LTMMar 2026
-$75.99M+22.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.6%+100.0%+60.4 pp
1 year+1.0%+100.0%+99.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(88.21M) USD
Year-over-year change
+1.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.0% is the 3rd highest of 8, against a peer median of +9.5%.
PEPG Competitors
EBITDA for PEPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.68M USD+23.9%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$43.73M USD+9.5%—8329.5%
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
PEPGPepGen Inc.LTM Mar 2026-$75.99M USD+22.0%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.28M USD-67.4%——
NKTXNkarta, Inc.LTM Mar 2026-$90.7M USD+10.7%——
ALECAlector, Inc.LTM Mar 2026-$116.42M USD-1.3%—632.1%
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M USD+23.4%—1859.1%
Peer median (excluding PEPG) —+9.5%—1859.1%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.18M1.51M1.4M
Gross Profit00(1.18M)(1.51M)(1.4M)
Gross Margin—————
Research & Development23.8M54.08M68.13M76.48M71.04M
Selling, General & Admin8.11M14.22M16.64M21.26M22.57M
Operating Expenses27.11M68.3M83.58M96.23M92.22M
Depreciation & Amortization178K493K1.18M1.51M1.4M
EBITDA(27.1M)(64.91M)(77.37M)(89.09M)(88.21M)
EBITDA Margin—————
Operating Income(27.11M)(68.3M)(84.77M)(97.74M)(93.61M)
Operating Margin—————
Interest Income02.79M6.4M7.14M4.02M
Interest Expense00000
Other Income / Expenses(172K)2.9M6.21M7.14M4.01M
Income Before Tax(27.28M)(65.4M)(78.55M)(90.6M)(89.61M)
Pre-Tax Margin—————
Income Tax Expense03.71M73K(617K)49K
Net Income(27.28M)(69.1M)(78.63M)(89.98M)(89.66M)
Net Margin—————
EPS (Basic)(1.22)(4.42)(3.30)(2.85)(2.12)
EPS (Diluted)(1.22)(4.42)(3.30)(2.85)(2.12)
Weighted Avg Shares22.39M15.64M23.8M31.58M42.22M
Weighted Avg Shares (Diluted)22.39M15.64M23.8M31.58M42.22M

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.